Vanguard Group Inc. Has $357.43 Million Stake in Evolent Health, Inc. (NYSE:EVH)

Vanguard Group Inc. increased its position in shares of Evolent Health, Inc. (NYSE:EVH) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,821,331 shares of the technology company’s stock after buying an additional 226,691 shares during the quarter. Vanguard Group Inc. owned 9.37% of Evolent Health worth $357,429,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Genesee Capital Advisors LLC boosted its position in Evolent Health by 2.2% during the 4th quarter. Genesee Capital Advisors LLC now owns 38,390 shares of the technology company’s stock worth $1,268,000 after acquiring an additional 825 shares during the last quarter. ICA Group Wealth Management LLC acquired a new position in Evolent Health during the fourth quarter worth $33,000. Principal Financial Group Inc. grew its position in Evolent Health by 10.4% in the fourth quarter. Principal Financial Group Inc. now owns 12,716 shares of the technology company’s stock valued at $420,000 after purchasing an additional 1,202 shares in the last quarter. Signaturefd LLC increased its stake in Evolent Health by 1,470.7% in the 4th quarter. Signaturefd LLC now owns 1,445 shares of the technology company’s stock valued at $48,000 after buying an additional 1,353 shares during the last quarter. Finally, Strs Ohio lifted its position in Evolent Health by 46.3% during the 4th quarter. Strs Ohio now owns 6,000 shares of the technology company’s stock worth $198,000 after buying an additional 1,900 shares in the last quarter.

Analyst Ratings Changes

A number of analysts recently issued reports on EVH shares. JPMorgan Chase & Co. lowered their target price on Evolent Health from $53.00 to $52.00 and set an “overweight” rating on the stock in a research report on Friday, March 15th. JMP Securities cut their price objective on Evolent Health from $38.00 to $34.00 and set a “market outperform” rating for the company in a report on Friday, May 10th. Oppenheimer assumed coverage on shares of Evolent Health in a research note on Friday, March 1st. They issued an “outperform” rating and a $45.00 target price for the company. Citigroup started coverage on shares of Evolent Health in a research note on Monday, April 22nd. They issued a “buy” rating and a $40.00 price target for the company. Finally, Canaccord Genuity Group lowered their price objective on shares of Evolent Health from $44.00 to $41.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Evolent Health Price Performance

Shares of NYSE EVH opened at $19.10 on Friday. The firm has a market cap of $2.22 billion, a P/E ratio of -15.28 and a beta of 1.44. The business’s 50 day moving average is $23.99 and its 200-day moving average is $28.95. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.57. Evolent Health, Inc. has a 1-year low of $18.86 and a 1-year high of $35.00.

Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Thursday, May 9th. The technology company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.04. The firm had revenue of $639.65 million for the quarter, compared to analysts’ expectations of $601.60 million. Evolent Health had a positive return on equity of 6.90% and a negative net margin of 5.07%. Equities research analysts predict that Evolent Health, Inc. will post 0.9 earnings per share for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.